secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cytek Biosciences, Inc. (CTKB)
CIK:        0001831915
Form:       8-K
Filed at:   2023-02-28T23:59:59+00:00
Accession:  0001193125-23-052702
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cytek Biosciences completes $46.5M acquisition of Luminex flow cytometry assets
-------------------------------------------------------------------------------

- Closed acquisition of Luminex's flow cytometry and imaging business (Amnis, CellStream, Guava, Muse brands) on Feb 28, 2023.
- Purchase price approximately $46.5 million in cash, subject to customary adjustments at closing.
- Company assumed certain liabilities of the acquired business.
- Financial statements and pro forma information to be filed within 71 days after this 8-K.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1831915/000119312523052702/0001193125-23-052702-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1831915/000119312523052702/d331452d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-052702

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer